Clinical trial
Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed…
NCT00291343 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00291343 |
|---|---|
| Title | Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study |
| Official title | Booster Vaccination Study to Assess Immunogenicity & Safety of a Dose of GSK Biologicals' Mencevax™ ACWY & 1/5th of a Dose of Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Meningococcal |
| Intervention type | Biological |
| Interventions | Tritanrix™- HepB, Hiberix™, Mencevax™ ACWY |
| Enrollment | 296 |
| Start date | Feb 1, 2006 |
| Primary completion | Mar 15, 2007 |
| Completion | Mar 15, 2007 |
| First posted | Feb 14, 2006 |
| Last update posted | Jun 6, 2018 |
| Countries | Philippines |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: